The immunosuppressive medications azathioprine and mycophenolate mofetil are similarly effective at controlling symptoms of generalized myasthenia gravis (gMG), but mycophenolate mofetil tends to act more quickly, according to a study in the U.S. Data also indicated that both medications were generally more effective when combined with corticosteroids, a…
News
Surgical removal of the thymus, or thymectomy, significantly improves nerve-muscle communication and eases symptoms and their impact on daily activities in children and adolescents with juvenile myasthenia gravis (JMG), a small U.S. study showed. After thymectomy, young patients not only showed measurable improvements in how efficiently their nerves…
In real-world practice, Vyvgart (efgartigimod alfa) is generally well tolerated and often effective for adults with generalized myasthenia gravis (gMG) who are positive for antibodies against the acetylcholine receptor (AChR) protein, a study showed. However, responses vary across patients and are often not durable, data showed. “These findings highlight…
Cartesian Therapeutics’ experimental cell therapy Descartes-08 outperformed a placebo at easing symptoms of generalized myasthenia gravis (gMG) in patients who test positive for self-reactive antibodies targeting the acetylcholine receptor (AChR) protein. That’s according to a new subgroup analysis of the Phase 2b MG-001 clinical trial (NCT04146051). Previous…
Rystiggo (rozanolixizumab-noli) provides consistent symptom relief for people with generalized myasthenia gravis (gMG) across more than a dozen treatment cycles, according to a new analysis of clinical trial data. The approved UCB therapy is given as weekly subcutaneous, or under-the-skin, infusions in six-week cycles, with additional cycles…
At this year’s Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, researchers and clinicians are talking about the central role of patients, families, and caregivers in driving change for people living with neuromuscular diseases. Bionews, the parent company of this site, sat down with John F. Crowley, president and…
Johnson & Johnson (J&J) has launched a Phase 3b clinical trial to compare the efficacy of two approved treatments for generalized myasthenia gravis (gMG). The trial, dubbed EPIC (NCT07217587), is specifically testing J&J’s Imaavy (nipocalimab) against Argenx’s Vyvgart (efgartigimod) in adults with gMG who…
Recovery after a myasthenia gravis (MG) exacerbation — a flare up or sudden worsening of disease symptoms — may take many months, even with the newer treatment options now available to MG patients. That’s according to a small study in Germany that followed 12 people with MG, treated with…
People with myasthenia gravis (MG) have higher psychological distress, including depression and anxiety, more frequent sleep problems, and greater cognitive difficulties than healthy people, according to a study in Italy. In addition, more severe disease and treatment with higher doses of corticosteroids were independent predictors of psychiatric symptoms…
Four weekly under-the-skin injections of Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) led to a marked reduction in double vision and drooping eyelids in adults with ocular myasthenia gravis (MG), according to top-line Phase 3 results. These findings come from the global Phase 3 ADAPT OCULUS clinical trial (NCT06558279),…
Recent Posts
- MMF treatment may act faster than azathioprine for gMG: Study
- The pain of having myasthenia gravis is real, but there is joy in it, too
- Honoring those who care for others by ensuring no one is forgotten
- Thymectomy eases symptoms for children, teens with juvenile MG
- Real-world study finds Vyvgart often effective in gMG, but responses vary